dc.contributor.author | Yaqub, Sheraz | |
dc.contributor.author | Bjørnbeth, Bjørn Atle | |
dc.contributor.author | Angelsen, Jon-Helge | |
dc.contributor.author | Fristrup, Claus W. | |
dc.contributor.author | Grønbech, Jon Erik | |
dc.contributor.author | Hemmingsson, Oskar | |
dc.contributor.author | Isaksson, Bengt | |
dc.contributor.author | Juel, Ingebjørg Soterud | |
dc.contributor.author | Larsen, Peter Nørgaard | |
dc.contributor.author | Lindell, Gert | |
dc.contributor.author | Mortensen, Frank V. | |
dc.contributor.author | Mortensen, Kim Erlend | |
dc.contributor.author | Rizell, Magnus | |
dc.contributor.author | Sandström, Per | |
dc.contributor.author | Sandvik, Oddvar Mathias | |
dc.contributor.author | Sparrelid, Ernesto | |
dc.contributor.author | Taflin, Helena | |
dc.contributor.author | Taskén, Kjetil | |
dc.contributor.author | Brudvik, Kristoffer Watten | |
dc.contributor.author | Fretland, Åsmund Avdem | |
dc.contributor.author | Horn, Arild | |
dc.contributor.author | Kleive, Dyre | |
dc.contributor.author | Labori, Knut Jørgen | |
dc.contributor.author | Lassen, Kristoffer | |
dc.contributor.author | Røsok, Bård Ingvald | |
dc.contributor.author | Søreide, Jon Arne | |
dc.contributor.author | Tholfsen, Tore | |
dc.contributor.author | Villanger, Olaug | |
dc.contributor.author | Waage, Anne | |
dc.date.accessioned | 2022-02-04T14:29:50Z | |
dc.date.available | 2022-02-04T14:29:50Z | |
dc.date.created | 2022-01-12T14:09:32Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Trials. 2021, 22 (1), . | en_US |
dc.identifier.issn | 1745-6215 | |
dc.identifier.uri | https://hdl.handle.net/11250/2977249 | |
dc.description.abstract | Background: Colorectal cancer is one the most common cancers in the western world with increasing incidence. Approximately 50% of the patients develop liver metastases. Resection of liver metastases is the treatment of choice although almost half of the resected patients get recurrence in the liver. Methods: The ASAC trial is a Scandinavian, multicentre, double-blinded, randomized, placebo-controlled study to determine whether adjuvant treatment with low-dose aspirin (acetylsalicylic acid (ASA)) can improve disease-free survival in patients treated for colorectal cancer liver metastases (CRCLM). Up to 800 patients operated for CRCLM will be randomized to Arm#1 ASA 160 mg once daily or Arm#2 Placebo, for a period of 3 years or until disease recurrence. The patients will be recruited at all major hepatobiliary surgical units in Norway, Sweden and Denmark and have follow-up according to standard of care and the National Guidelines. Discussion: The ASAC trial will be the first clinical interventional trial to assess the potential beneficial role of ASA in recurrence of CRCLM and survival. ASA is an inexpensive, well-tolerated and easily accessible drug that will be highly potential as adjuvant drug in secondary prevention of CRCLM if the study shows a beneficial effect. We will also determine the effect of ASA as adjuvant treatment on Health-Related Quality of Life and the cost-effectiveness. Trial registration: ClinicalTrials.gov NCT03326791. Registered on 31 October 2017. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | BMC | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.pagenumber | 0 | en_US |
dc.source.volume | 22 | en_US |
dc.source.journal | Trials | en_US |
dc.source.issue | 1 | en_US |
dc.identifier.doi | 10.1186/s13063-021-05587-w | |
dc.identifier.cristin | 1979520 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |